Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
Dermatol Reports
.
2022 Mar 17;14(3):9282.
doi: 10.4081/dr.2022.9282.
eCollection 2022 Sep 14.
Authors
Luca Mastorino
1
,
Niccolò Siliquini
1
,
Gianluca Avallone
1
,
Michela Ortoncelli
1
,
Pietro Quaglino
1
,
Paolo Dapavo
1
,
Simone Ribero
1
Affiliation
1
Medical Science Department, Section of Dermatology, University of Turin, Italy.
PMID:
36199899
PMCID:
PMC9527684
DOI:
10.4081/dr.2022.9282
No abstract available
Keywords:
Biological therapy; Cancer; Guselkumab; IL-23; Neoplasia; Psoriasis.
Grants and funding
Funding: None.